top of page

Ahead of ASCO, Corbus is providing updated data today on its Nectin-4 ADC in cervical and head and neck cancer - and has seen that response rate appears to be directly related to HPV status

42 minutes ago
1 min read

In 2L cervical cancer, the company saw a confirmed ORR of 34.4% (n=70), In the highest dose used in 2L oropharyngeal squamous cell carcinoma, a subset of head and neck patients whose cancers are primarily driven by HPV, Corbus saw a confirmed ORR of 42.9% (n=21). CEO Yuval Cohen walks us through his analysis of the data.

Recent Posts

See All

Biotech's movers for the week of May 18th and a preview of the week ahead

Cartesian Therapeutics is working on CAR-T for autoimmune conditions, but with the unique angle that it is using a mRNA approach rather than DNA

Sutro Biopharma is developing next generation antibody-drug conjugates, including dual payload ADCs. CEO Jane Chung walks us through their programs

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more